Advances in Tuberculosis Research through Genome Sequencing

Understanding Drug Resistance in Tuberculosis

A team of international researchers has conducted an extensive analysis of the genome sequences from over 10,000 strains of tuberculosis (TB) to gain insights into drug resistance in TB treatment. Globally, TB is recognized as the deadliest infectious disease, with approximately 1.7 million fatalities and 10 million new cases reported in 2016. The disease is caused by the bacterium Mycobacterium tuberculosis, and antibiotic resistance complicates treatment, often rendering standard medications ineffective.

The Importance of Drug-Susceptibility Testing

The World Health Organization emphasizes the necessity of drug-susceptibility testing for each TB patient, enabling healthcare providers to select the most effective antibiotics for personalized treatment. However, these tests are resource-intensive and costly, limiting their availability in countries with high TB prevalence. Consequently, many patients may receive incorrect antibiotic combinations, diminishing their chances of recovery.

The Need for Rapid and Cost-Effective Testing

There is an urgent requirement for tests that can quickly and economically identify effective antibiotics for specific TB strains. Recent advancements in technology have made it feasible for researchers to conduct whole genome sequencing of various TB strains more efficiently and at a lower cost than traditional diagnostic methods.

Research Findings from the CRyPTIC Consortium

Led by the University of Oxford, the CRyPTIC Consortium analyzed over 10,000 Mycobacterium tuberculosis strains collected from 16 different countries. Through their genomic analysis, researchers identified gene mutations associated with drug resistance and susceptibility. They achieved a high accuracy rate (91-99%) in predicting which TB strains were resistant or susceptible to particular antibiotics. Their findings were published in the New England Journal of Medicine.

Significance of the Study

Stefan Niemann, the lead of the CRyPTIC study, stated, “This study enables new concepts for TB diagnostics to be developed. Additionally, standard resistance testing for commonly used drugs could soon be replaced by genome-based methods. This is a milestone and a paradigm shift in the fight against multi-drug resistant TB.”

References

The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018. DOI: 10.1056/NEJMoa1800474

Press Release: Paradigm shift in tuberculosis treatment: genome sequencing replaces standard resistance testing. https://www.eurekalert.org/pub_releases/2018-10/gcfi-psi100318.php